Skip to main content

EYPT

Stock
Health Care
Biotechnology

Performance overview

EYPT Price
Price Chart

Forward-looking statistics

Beta
1.69
Risk
97.26%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Company info

SectorHealth Care
IndustryBiotechnology
Employees150
Market cap$474.0M

Fundamentals

Enterprise value$353.4M
Revenue$56.0M
Revenue per employee—
Profit margin-261.91%
Debt to equity8.07

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.42
Dividend per share—
Revenue per share$0.93
Avg trading volume (30 day)$9M
Avg trading volume (10 day)$9M
Put-call ratio—

Macro factor sensitivity

Growth+5.6
Credit-0.1
Liquidity-0.8
Inflation+2.1
Commodities+0.6
Interest Rates-2.0

Valuation

Dividend yield0.00%
PEG Ratio-3.43
Price to sales11.93
P/E Ratio-3.43
Enterprise Value to Revenue6.31
Price to book2.24

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day—
Ex. dividend day—

News

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates

EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.65 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago.

Zacks Investment Research (May 7, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free